D-0337-2023 Class II Terminated
FDA drug recall D-0337-2023 was initiated by IBSA PHARMA INC on Jan 30, 2023 and is designated Class II. Reason for recall: Subpotent Drug The recall status is terminated (terminated Oct 31, 2023).
Recall details
- Product Type
- Drugs
- Report Date
- Mar 1, 2023
- Initiation Date
- Jan 30, 2023
- Termination Date
- Oct 31, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 44 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0113-5
Reason for recall
Subpotent Drug
Distribution pattern
Nationwide in the USA.
Code information
Lot #: 220553, Exp. 11/2023; 221056, Exp. 04/2024.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0337-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026